Data Published Today in the New England Journal of Medicine Demonstrates Anthos Therapeutics’ novel Factor XI inhibitor, Abelacimab 150mg, Reduced Major or Clinically Relevant Non-Major Bleeding by 62% Compared to Rivaroxaban (Xarelto) in Patient Yahoo Finance Nawigacja wpisu Improving MS Management Through Early Intervention and Precision Medicine: Emilio Portaccio, MD – Neurology Live
